Paclitaxel (Taxol®): A review of its antitumor activity in clinical studies. Minireview

Neoplasma

Volumn 43, Issue 3, 1996, Pages 141-154

  Hajek R ^a   Vorlicek J ^a   Slavik, M ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

antineoplastic agent; antitumor activity; clinical studies; paclitaxel; Taxol

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MOUSE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; REVIEW; BREAST TUMOR; DRUG EFFECT; HEAD AND NECK TUMOR; LUNG TUMOR; MELANOMA; MICROTUBULE; NEOPLASM; NERVOUS SYSTEM TUMOR; OVARY TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MELANOMA; MICROTUBULES; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0029661912     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. ABRAMS, J.S., VENA, D.A., BALTZ, J., ADAMS, J., MONTELLO, M., CHRISTIAN, M., ONETTO, N., CANETTA, R., FRIEDMAN, M.A., ARBUCK, S.G.: Paclitaxel (Taxol) activity in heavily treated metastatic breast cancer (MBC). Abstr. 494. Ann. Oncol., Suppl. 5, 5, 1994, 199.
2. AJANI, J.A., ILSON, D., DAUGHERTY, K., PAZDUR, R., LYNCH, P.M., KELSEN, D.P.: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer. Inst., 20, 1994, 1086-1091.
3. ARAVANTIOS, G., SKARLOS, D., KOSMIDIS, P., ATHANASIADIS, A., BAFALOUKOS, D., GIANNAKAKIS, TH., PAPANTONAKIS, E., FOUNTZILAS, G.: Taxol in platinum pretreated ovarian cancer patients. Abstr. 510. Ann. Oncol., Suppl. 8, 5, 1994, 102.
4. ARBUCK, S.G., CANETTA, R., ONETTO, N., CHRISTIAN, M.C.: Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin. Oncol., 20, 1993, 31-39.
5. ATHANASSIOU, A., PECTASIDES, D., VARTHALITIS, L, DIMITRIADES, M., TSILIAKOS, S., PAPAZACHARIOU, A.: Taxol patients with cis/carboplatin-refractory ovarian carcinoma. Abstr. 870. Proc. Am. Soc. Clin. Oncol., 13, 1994, 271.
6. BEHRENS, B., COPELAND, L., BALCERZAK, S., STAUBUS, A., VANDRE, D., VILLASMIL, P.: A phase I Taxol/altretamine doublet clinical trial in women with refractory ovarian cancer. NCI #T92-0014, Abstr. 868. Proc. Am. Soc. Clin. Oncol., 13, 1994, 13, 271.
7. BELANI, C.P., HIPONIA, D., ENGSTROM, C., AISNER, J.: Phase I study of paclitaxel and carboplatin in advanced and metastatic non-small cell lung carcinoma. Abstr. 381. Proc. Am. Soc. Clin. Oncol., 14, 1995, 174.
8. BELLI, L., LE CHEVALIER, T., GOTTFRIED, M., ADAMS, D., RUFFIÉ, P., LE CESNE, A., TETE, L., PELLAE-COSSET, B.: Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC). Abstr. 1058. Proc. Am. Soc. Clin. Oncol., 14, 1995, 350.
9. BERRY, J., EZZAT, A., EL-WARITH, RAJA, M.A., BAZARBASHI, S.: Sequential Taxol/platinum: Pilot study in metastatic breast cancer. Abstr. 243. Proc. Am. Soc. Clin. Oncol., 14, 1995, 136.
10. BONOMI, P., CELLA, D., CHANG, A. for Eastern Cooperative Oncology Group: Phase III trial comparing etoposide/cisplatin versus Taxol/cisplatin/G-CSF versus Taxol/cisplatin in advanced non small cell lung cancer. Study #E5592. In: Clinical Experience in Non Small Cell Lung Cancer. Taxol. Bristol-Myers Oncology Division product, 1994, 27.
11. BOOKMAN, M.A., MCGUIRE, W.P., KILPATRICK, D., KEENAN, E., JOHNSON, S., O'DWYER, P., ROWINSKY, E., OZOLS, R.F.: Phase I gynecologic oncology group (gog) study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (ovca). Abstr. 755. Proc. Am. Soc. Clin. Oncol., 14, 1995, 271.
12. BROWN, T., TANGEN, C., FLEMING, T., MACDONALD, J.: A phase II trial of taxol and granulocyte colony stimulating factor in patients with adenocarcinoma of the pancreas. Abstr. 592. Proc. Am. Soc. Clin. Oncol., 12, 1993, 200.
13. BROWNE, M.J., KENNEDY, T., CUMMINGS, SIKOV, W., AKERLEY, W., DONEHOWER, R., CLARK, J.W.: Phase II study of sequential Taxol and cisplatin for the treatment of metastatic breast cancer. Abstr. 245. Proc. Am. Soc. Clin. Oncol., 14, 1995, 136.
14. BRUCKNER, H.W., CAGNONI, P.J., LEE, J.M., CHESSER, M.R., ANDREOTTI, P.E.: A sequence of adriamycin and Taxol infusions for refractory ovarian cancer. Abstr. 890. Proc. Am. Soc. Clin. Oncol., 13, 1994, 276.
15. BURTNESS, B., HENDERSON-BAKAS, M., D'ANDREA, E.: Single agent paclitaxel mobilizes CD34 + cells effectively. Abstr. 131. Proc. Am. Soc. Clin. Oncol., 14, 1995, 108.
16. CAGNONI, P.J., STEMMER, S.M., MATTHES, S., DUFTON, C., BEARMAN, S.I., SHPALL, E.J., PURDY, M.H., ARRON, J., DAY, T., TAFFS, S., JONES, R.B.: Phase I trial of high dose paclitaxel (Taxol), cyclophosphamide (CPA) and cisplatin (CDDP) with autologous hematopoetic progenitor cell (AHPC) rescue. Abstr. 1548. Proc. Am. Soc. Clin. Oncol., 14, 1995, 477.
17. CHANG, A.Y., KIM, K., GLICK, ANDERSON, T., KARP, D., JOHNSON, D.: Phase II study of Taxol, merbarone, and piroxantrone in Stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J. Natl. Cancer. Inst., 85, 1993, 388-394.
18. CHITTY, C., JOYCE, R., MARKS, A.: Hematopoetic tolerance to Taxol following marrow ablative chemotherapy and stem cell rescue for treatment of metastatic breast carcinoma. Abstr. 186. Proc. Am. Soc. Clin. Oncol., 13, 1994.
19. CHOY, H., AKERLEY, W., SAFRAN, G., CLARK, J., REGE, V., PAPA, A., GLANTZ, M., PUTHAWALA, Y., SODERBERG, C., LEONE, L.: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J. Clin. Oncol., 12, 1994, 2682-2686.
20. CROWN, J., FENNELLY, D., SCHNEIDER, J., HAKES, T., BENGALA, C., MCKENZIE, M., REICH, L., BARAKAT, R., CURTIN, J., SPRIGGS, D., HOSKINS, W., NORTON, L.: Escalating dose Taxol + high-dose cyclophosphamide/G-CSF as induction and to mobilize peripheral blood progenitors for use as rescue following multiple courses of HD carboplatin/C: A phase I trial in ovarian cancer patients. Abstr. 831. Proc. Am. Soc. Clin. Oncol., 13, 1994, 264.
21. DEMETRI, G.D., BERRY, D., YOUNGER, J, ROBERT, N.J., DUGGAN, D., STONER, P., HENDERSON, I.C.: Dose-intensified cyclophosphamide/doxorubicin followed by Taxol as adjuvant systemic chemotherapy for node positive breast cancer (Calgb. 9141): Randomized comparison of two dose levels of G-CSF. Abstr. 63. Proc. Am. Soc. Clin. Oncol., 13, 1994, 65.
22. DIERAS, V., MARTY, M., MORVAN, F., TUBIANA, N., CORETTE, L., MIGNOT, L., SERIN, D., CHAZARD, M., GARET, F., ONETTO, N., HELLMANN, S., POUILLART, P.: A phase II randomized study of Taxol versus Mitomycin C in patients with advanced breast cancer: Interim analysis. Abstr. 1683. Proc. Am. Soc. Clin. Oncol., 13, 1994, 112.
23. DIMOPOULOS, M., ARBUCK., S., HUBER, M., WEBER, D., LUCKETT, R., DELASALLE, KL, ALEXANIAN, R.: Primary therapy of multiple myeloma with paclitaxel (Taxol). Ann. Oncol., 5, 1994, 757-759.
24. DONFRANCESCO, A., DEB, G., SIO, L., HABETSWALLNER, D., HELSON, L.: Phase I trial of a Q4D Taxol regimen in pediatric patients with recurrent solid tumors. Abstr. 1463. Proc. Am. Soc. Clin. Oncol., 13, 1994, 427.
25. DOUROS, J., SUFFNESS, M.: New natural products under development at the National Cancer Institute. Recent Results. Cancer. Res., 76, 1981, 153-175.
26. DUNPHY, F., BOYD, J., VARVARES, M., KIM, H., DUNPHY, C.: Preoperative chemotherapy with paclitaxel/paraplatin (P/P) in head and neck squamous cell carcinoma. Preliminary results of phase I/II trial. Abstr. 869. Proc. Am. Soc. Clin. Oncol., 14, 1995, 300.
27. EISENHAUER, E.A., TEN BOKKEL HUININK, W.W., SWENERTON, K.D. et al.: Europen-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J. Clin. Oncol., 12, 1994, 2654-2666.
28. EINZIG, A.I., GOROWSKI, E., SASLOFF, J., WIERNIK, P.H.: Phase n trial of Taxol in patients with metastatic renal cell carcinoma. Cancer. Inv., 9, 1991, 133-136.
29. EINZIG, A.E., HOCHSTER, H., WIERNIK, P.H., TRUMP, D.L., DUTCHER, J.P., GAROWSKI, E., SASLOFF, J., SMITH, T.J.: A phase II study of Taxol in patients with malignant melanoma. Inv. New. Drugs., 9, 1991, 54-64.
30. EINZIG, A.I., WIERNIK, P.H., LIPSITZ, S., BENSON, A.B., MADISON, W.I.: Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group results. Abstr. 566. Proc. Am. Soc. Clin. Oncol., 12, 1993, 194.
31. EINZIG, A.E., WIERNIK, P.H., SASLOFF, J., RUNOWICZ, C.D., GOLDBERG, G.L.: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol., 10, 1992, 1748-1753.
32. ELKORDY, M., MATTERS, L., CONIGLIO, D., PETROS, W., VREDENBURGH, J., HUSSEIN, A., MEISENBERG, B., RUBIN, P., ROSS, M., PETERS, W.: The effect of continuous infusion 5-FU (CI-F) with or without Taxol as induction therapy in stage IV breast carcinoma. Abstr. 184. Proc. Am. Soc. Clin. Oncol., 13, 1994, 95.
33. ETTINGER, D.S., FINKELSTEIN, D.M., SARMA, R.: Phase II study of Taxol in patients with extensive stage small cell lung cancer: An Eastern Cooperative Oncology Group study. Abstr. 1094. Proc. Am. Soc. Clin. Oncol., 12, 1993, 329.
34. EVANS, W.K., STEWART, D.J., TOMIAK, E., GOSS, G., LOGAN, D., DULUDE, H., GALLANT, G.: Carboplatin and paclitaxel by one hour infusion for advanced non-small cell lung cancer (NSCLC). Abstr. 1156. Proc. Am. Soc. Clin. Oncol., 14, 1995, 374.
35. FELDMAN, E., SEITER, K., HELSON, L., TRAGANOS, F., GASTON, K., ROMERO, M.B., BEER, M.: Phase I evaluation of a short infusion every 4 day schedule of Taxol in refractory acute leukemia. Abstr. 1022. Proc. Am. Soc. Clin. Oncol., 13, 1994, 311.
36. FENNELLY, D., SCHNEIDER, J., SPRIGGS, D., BENGALA, C., HAKES, T., REICH, L., BARAKAT, R., CURTIN, J., MOORE, M.A.S., HOSKINS, W., NORTON, L., CROWN, J: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J. Clin. Oncol., 13, 1995, 1160-1166.
37. FETELL, M.R., GROSSMAN, S.A., BALMACEDA, C., LEU, J.G., ERLANGER, B.F., ROWINSKY, E., KHANDJI, G., YUE, N., ZELTMAN, M.: Clinical and pharmacological study of preirradiation Taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiforme. Abstr. 504. Proc. Am. Soc. Clin. Oncol., 13, 1994, 178.
38. FIELDS, K., PERKINS, J., ELFENBEIN, G., BALLESTER, O., HIEMENZ, J., GOLDSTEIN, S., ZORSKY, P., KRONISH, L.: A phase I dose escalation trial of high dose Taxol, Novantrone, and thiotepa (TNT) followed by autologous stem cell rescue. Abstr. 953. Proc. Am. Soc. Clin. Oncol., 14, 1995, 322.
39. FISHERMAN, J., MCCABE, M., HILLIG, M., GOLDSPIEL, B., COWAN, K.H., O'SHAUGHNESSY, J.A.: Phase I study of Taxol plus doxorubicin plus granulocyte colony stimulating factor (G-CSF) in patients with metastatic breast cancer. Second National Cancer Inst. Workshop on Taxol and Taxus, Alexandria, Sept. 23-24, 1992, 23-24.
40. FORASTIERE, A.A., NEUBURG, D., TAYLOR, S.G.: Phase II evaluation of Taxol in advanced head and neck cancer. An Eastern Cooperative Oncology Group trial. J. Natl. Cancer. Inst, 15, 1993, 181-184.
41. FORASTIERE, A.A., ROWINSKY, E., CHAUDRY, S.: Phase I trial of Taxol and cisplatin + G-CSF in solid tumors. Proc. Am. Soc. Clin. Oncol., 11, 1992, 117.
42. FORASTIERE, A.A., URBA, S.G., LIGGETT, W., MILLER, D.F.: Paclitaxel and ifosfamide combination chemotherapy in advanced head and neck cancer: Toxicity is sequence dependent Abstr. 845. Proc. Am. Soc. Clin. Oncol., 14, 1995, 294.
43. FRAZEIN, A., WASSERHEIT, C., HOCHSTER, H., ORATZ, R., WERNZ, J., CHACHOUA, A., MEYERS, M., SORICH, J., DOWNEY, A.: High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. Abstr. 145. Proc. Am. Soc. Clin. Oncol., 14, 1995, 111.
44. GEHL, J., EJLERSEN, B., BOESGAARD, M., DOMBERNOVSKY, P.: Efficacy and toxicity of combinated doxorubicin (D) and paclitaxel (P) in metastatic breast cancer. Preliminary results. Abstr. 192. Ann. Oncol., Suppl. 8, 5, 1994, 39.
45. GELMON, K., NABHOLTZ, J.M., BONTENBAL, M., SPIELMANN, M., CONTE, P., KLAASSEN, U., CATIMEL, G., NAMER, M., FUMOLEAU, J., BONNETERRE, P., SULKES, A., SAUTER, CH., ROCHE, H., CALVERT, H., KAUFMANN, J.: Randomized trial of two doses of paclitaxel in metastatic breast cancer after failure of standard therapy. Abstr. 493. Ann. Oncol., Suppl. 5, 5, 1994, 198.
46. GELMON, K.A., O'REILLY, S., PLENDERLEITH, I.H., BRYCE, C., RAGAZ, J., COPPIN, C., CAMPBELL, C., HEALEY, D., ONETTO, N.: Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Abstr. 87. Proc. Am. Soc. Clin. Oncol., 13, 1994, 71.
47. GIACCONE, G., HUIZING, M., HUININK, W.T., KOOLEN, M., POSTMUS, P., VANKRALINGEN, K., VANZANDWIJK, N., VERMORKEN, J., BEIJNEN, J., DALESIO, O., PINEDO, H., VEENHOF, C.: Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: A European Cancer Centre effort. Semin. Oncol., Suppl. 8, 21, 1994, 34-38.
48. GIACCONE, G., SPLINTER, T.A.W., POSTMUS, P., VAN MEERBEECK, J., DEBRUYNE, C., SAHMOUD, T.: Teniposide-cisplatin vs paclitaxel-cisplatin in advanced non-small cell lung cancer (NSCLC). Results of a randomized phase II study of the EORTC-LCCG. Abstr. 1082. Proc. Am. Soc. Clin. Oncol., 14, 1995, 356.
49. GIANNI, L., CAPRI, G., MUNZONE, E., STRANEO, M.: Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin. Oncol., Suppl. 8, 21, 1994, 29-33.
50. GIANNI, L., STRANEO, M., CAPRI, G., VILLANI, E., MUNZONE, E., BONADONNA, G.: Optimal dose and sequence finding study of paclitaxel by 3h infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Abstr. 97. Proc. Am. Soc. Clin. Oncol., 13, 1994, 74.
51. GLANTZ, L., CHOY, H., COLE, B., MILLS, P., KNUCKEY, N., STOPA, E.: Phase I study of weekly, out-patient Taxol and concurrent cranial radiation in adults with astrocytomas. Abstr. 279. Proc. Am. Soc. Clin. Oncol., 14, 1995, 146.
52. GLANTZ, M.J., CHOY, H., KEARNS, C.H.M., MILLS, P.C., WAHLBERG, L.U., ZUHOWSKI, E.G., CALABRESI, P., EGORIN, M.J.: Paclitaxel disposition in plasma and central nervous systems of human and rats with brain tumors. J. Natl. Cancer. Inst., 87, 1995, 1077-1081.
53. GLANTZ, L., CHOY, H., STOPA, E., KLEIN, A., WALHBERG, L., CHOUGULE, P., GLANTZ, M.: Histological response analysis of brain tumors following concurrent Taxol and radiation therapy. Abstr. 522. Proc. Am. Soc. Clin. Oncol., 13, 1994.
54. GORE, M.E., PRESTON, N., HILL, C., NICOLSON, M., CHANG, J., MITCHELL, P.: Taxol-platinum noncross-resistance in epithelial ovarian cancer (EOC): The Royal Marsden hospital experience. Abstr. 496. Ann. Oncol., Suppl. 5, 5, 1994, 199.
55. GORE, M.E., RUSTIN, G., SLEVIN, M., GALLAGHER, C., OSBORNE, R., LEDERMANN, J., CAMERON, T., THOMPSON, J.M.: Single agent paclitaxel in previously untreated patients with stage IV epithelial ovarian cancer. Abstr. 747. Proc. Am. Soc. Clin. Oncol., 14, 1995, 269.
56. GRECO, F.A., HAINSWORTH, J.D.: Paclitaxel (Taxol): Phase I/II trial comparing 1-hour infusion schedules. Sem. Oncol., Suppl. 8, 5, 1994, 3-8.
57. GREENBERG, R., FRIEDLAND, D., HOLROYDE, C., TERZIAN, A., LERNER, W.: Phase II trial of Taxol and adriamycin in stage IV non-smail cell lung cancer. Abstr. 1157. Proc. Am. Soc. Clin. Oncol., 14, 1995, 374.
58. GREM, J.L., TUTSCH, K.D., SIMON, K.J.: Phase I study of Taxol administered as a short i.v. infusion daily for 5 days. Cancer. Treat. Rep., 71, 1987, 1179-1184.
59. HAINSWORTH, J.D., MCKAY, C.E., MILLER, M.S., GRECO, F.A.: Treatment of small cell lung cancer (SCLC) with Taxol (one-hour infusion), carboplatin and low dose daily etoposide: Phase II study of an outpatient regiment. Abstr. 1197. Proc. Am. Soc. Clin. Oncol., 14, 1995, 384.
60. HAINSWORTH, J.D., STROUP, S.L., SPIGEL, S.C., MENCHISE, A.E., GRECO, F.A.: Treatment of locally advanced, unresectable non-small ceil lung cancer (NSCLC) with paclitaxel (1-hour infusion), cisplatin, etoposide and radiation therapy: A phase II trial. Abstr. 1192. Proc. Am. Soc. Clin. Oncol., 14, 1995, 383.
61. HAINSWORTH, J.D., THOMPSON, D.S., SPIGEL, S.C., PETERS, M.H., GRECO, F.A.: Paclitaxel by 1-hour infusion in the treatment of stage IV or relapsed non-small cell lung cancer (NSCLC). Abstr. 1116. Proc. Am. Soc. Clin. Oncol., 14, 1995, 364.
62. HITT, R., HORNEDO, J., COLOMER, R., MENDIOLA, C., BRANDARIZ, A.: Phase I/II study of escalating doses of Taxol + cisplatin with G-CSF (Filgrastin) as first-line therapy for head and neck carcinomas. Abstr. 868. Preliminary results. Proc. Am. Soc. Clin. Oncol., 14, 1995, 300.
63. HOEKMAN, K., HUUSKES, R.V, BURGER, C.W.: Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum. Ned. Tijdschr. Geneeskd., 139, 1995, 272-278.
64. HOLMES, F.A., FRYE, D., VALERO, V., WALTERS, R.L., THERIAULT, R.L., BOOSER, D., VADAN-RAJ, S., HORTOBAGYI, G.N.: Phase I study of Taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Abstr. 66. Proc. Am. Soc. Clin. Oncol., 11, 1992, 60.
65. HOLMES, F.A., NEWMAN, R.A., MADDEN, T., VALERO, V., FRASCHINI, G., WALTERS, R.S., BOOSER, D.J., BUZDAR, A.U., WILEY, J., HORTOBAGYI, G.N.: Schedule dependent pharmacokinetics (PK) in a phase I trial of Taxol (T) and Doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Abstr. 489. Ann. Oncol., Suppl. 5, 5, 1994, 197.
66. HOLMES, F.A., VALERO, V., THERIAULT, R.L., WALTERS, R.S., BOOSER, D.B., FRYE, D., HORTOBAGYI, D.N.: Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Abstr. 178. Proc. Am. Soc. Clin. Oncol., 13, 1993, 94.
67. HOLMES, F.A., WALTERS, R.S., THERIAULT, R.L., FORMAN, A.D., NEWTON, L.K., RABER, M.N., BUZDAR, A.U., FRYE, D.K., HORTOBAGYI, G.N.: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer. Inst., 83, 1991, 1797-1805.
68. HOLMES, F.A., WALTERS, R., VALERO, V., THERIAULT, R., BOOSER, D., BUZDAR, A., GIBBS, H., FRYE, D., HORTOBAGYI, G.: The M.D. Anderson experience with Taxol in metastatic breast cancer. Second National Cancer Inst. Workshop on Taxol and Taxus, Alexandria, September 23-24, 1992, 19-20.
69. HOPFINGER, G., HEINZ, R., WALDNER, R., SCHLOGL, E., PFEILSTÖCKER, M., PITTERMANN, E.: Paclitaxel in the treatment of lymphomas. Abstr. 69. Ann. Oncol., Suppl. 8, 5, 1994, 139.
70. KAVANAGH, J.J., KUDELKA, A.P., EDWARDS, C.L.: A randomized crossover trial of parenteral hydroxyurea vs. high dose Taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Ann. Oncol., Suppl. 8., 5, 1993, 259.
71. KAWAUCHI, R., BONOMI, P., FABER, L.P.: Phase I trial of escalating doses ofTaxol combined with carboplatin, cisplatin, etoposide and simultaneous thoracic radiation therapy in stage III non-small cell lung cancer (NSCLC). Abstr. 1193. Proc. Am. Soc. Clin. Oncol., 14, 1995, 383.
72. KENEDY, M.J., ARMSTRONG, D., DONEHOWER, R., NOE, D., SARTORIUS, S., CHEN, T.L., BOWLING, K., ROWINSKY, E.: The hematologic toxicity of the Taxol/Cytoxan doublet is sequence-dependent. Abstr. 342. Proc. Am. Soc. Clin. Oncol., 13, 1994, 137.
73. KIRSCHLING, R.J., JUNG, S.H., JETT, J.R.: A phase II trial of Taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer. Abstr. 1076. Proc. Am. Soc. Clin. Oncol., 13, 1994, 326.
74. KLAASSEN, U., WILKE, H., PHILIPPOU, C., STRUMBERG, D., HARSTRICK, A., EBERHARDT, W., DIERGARTEN, K., LENAZ, L.: Phase I/II study with paclitaxel (T) in combination with weekly high dose 5-FU/Folinic Acid (HD-FU/FA) in the treatment of metastatic breast cancer (MBC). Abstr. 186. Proc. Am. Soc. Clin. Oncol., 14, 1995, 122.
75. KLAASSEN, U., DIERGARTEN, K., DITTRICH, CH.: Randomized trial of two doses of Taxol in metastatic breast cancer: An interim analysis. Onkologie, 17, 1994, 86-90.
76. KLASTERSKY, J., SCULIER, J.P.: A dose-finding study paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. Sem. Oncol., Suppl. 8, 5, 1994, 39-43.
77. KOHN, E., REED, E., LINK, C., CHRISTIAN, M., DAVIS, P., SAROSY, G.: A pilot study of Taxol, cisplatin cyclophosphamide and G-CSF in newly diagnosed stage III/IV ovarian cancer patients. Abstr. 814. Proc. Am. Soc. Clin. Oncol., 12, 1993, 257.
78. KOHN, E.C., SAROSY, G., BICHER, A., LINK, CH., CHRISTIAN, M., STEINBERG, S.M., ROTHENBERG, M., ADAMO, D.O.: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer. Inst., 86, 1994, 18-24.
79. KRIS, M.G., O'CONELL, J.P., GRALLA, R.: Phase I trial of Taxol given as a 3-hours infusion every 21 days. Cancer. Treat Rep., 70, 1986, 605-607.
80. LANGER, C.J., LEIGHTON, J., COMIS, R., MCALEER, C., BONJO, C.: Paclitaxel (Taxol) and carboplatin (CBDCA) in advanced and IIIB non-small cell lung cancer (NSCLC): Toxicity, response and survival update. Abstr. 1080. Proc. Am. Soc. Clin. Oncol., 14, 1995, 355.
81. LEDERMAN, G., ODAIMI, N., WERTEIM, S., LOWRY, J., FINE, M., SILVERMAN, P., KLEIN, E.: Taxol and fractionated radiosurgery (FRS) for recurrent high grade primary brain tumors (RBT). Abstr. 309. Proc. Am. Soc. Clin. Oncol., 14, 1995, 153.
82. LEGRA, S.S., RING, S., PAPADOPOULOS, N., RABER, M., BENJAMIN, R.S.: A phase II trial of Taxol in metastatic melanoma. Cancer, 65, 1991, 2478-2481.
83. LIEBMANN, J., COOK, J.A., FISHER, TEAGUE, D., MITCHELL, J.B.: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer. Inst, 86, 1994, 441-446.
84. LINK, C.J. JR., BICHER, A., KOHN, E.C., CHRISTIAN, M. C., DAVIS, P.A., ADAMO, D.O., REED, E., SAROSY, G.A.: Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense Taxol therapy. Blood, 83, 1994, 1188-1192.
85. National Cancer Institute: Clinical Bronchure: Taxol (NSC 125973). Bethesda, MD Division of Cancer Treatment, NCI 1991.
86. MAMOUNAS, E., BROWN, A., FISHER, B., WICKERHAM, D.L., SIDHOM, M., ATKINS, J., DESCH, C., STOLLER, R., FEHRENBACHER, L.: 3-hour hig-dose Taxol infusion in advanced breast cancer (ABC): An NSABP phase II study. Abstr. 206. Proc. Am. Soc. Clin. Oncol., 14, 1995, 127.
87. MANEGOLD, C., RIECHE, K., FRITZE, D., NACIEMENTO, M., DIERGARTEN, K., DRINGS, P.: Phase n Study with Paclitaxel (Taxol) in advanced non-small cell lung cancer. Abstr. 772. Ann. Oncol., Suppl. 8, 5, 1994, 154.
88. MARKMAN, M., HAKES, T., RIECHMAN, B., SCHNEIDER, J., RUBIN, S., LEWIS, J.L., BARAKAT, R.: Memorial Sloan-Kettering Cancer Center experience with National Cancer Institute treatment referral center Protocol 9103:Taxol in refractory ovarian cancer. Abstr. 851. Proc. Am. Soc. Clin. Oncol., 12, 1993, 266.
89. MARKMAN, M., FRANCIS, P., ROWINSKY, E., HAKES, T., REICHMAN, B., JONES, W., LEWIS, J.L., RUBIN, S., CURTIN, J., BARAKAT, R., PHILLIPS, M., HOSKINS, W.: Rationale for the intraperitoneal administration of paclitaxel (Taxol) in the treatment of ovarian cancer. Int. J. Gynecol. Cancer., Suppl. 1, 4, 1994, 19-22.
90. MCGUIRE, W.P., HOSKINS, W.J., BRADY, M.F., KUCERA, P. R., PARTRIDGE, E.E., LOOK, K.Y., DAVIDSON, M.: Taxol and cisplatin (TP) improves outcomes in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Abstr. 771. Proc. Am. Soc. Clin. Oncol., 14, 1995, 275.
91. MCGUIRE, W.P., ROWINSKY, E.K., ROSENHEIM, N.B., GRUMBINE, F.C., ETTINGER, D.S., ARMSTRONG, D.K., DONEHOWER, R.C.: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Int. Med., 111, 1989, 273-279.
92. MENDIOLA, C., GARCIA-RIBAS, I., CUBEDO, R., COLOMER, R., HITT, R.: High response rate of Taxol in platinum pretreated advanced ovarian cancer. Abstr. 783. Proc. Am. Soc. Clin. Oncol., 14, 1995, 278.
93. MOTZER, R.J., BAJORIN, D.F., SCHWARTZ, HUTTER, H.S., BOSL, G.J., SCHER, H.I., LYN, P., FISCHER, P.: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol., 12, 1994, 2277-2283.
94. MUNZONE, E., CAPRI, G., FULFARO, F., TARENZI, E., CARACENI, A., VILLANI, F., SPREAFICO, C., LAFFRANCHI, A., CRABEELS, D., GIANNI, L.: Paclitaxel (P) by 3 H schedule in relapsed breast cancer (BC) resistant to anthracycline (A). Abstr. 212. Ann. Oncol., Suppl. 8, 5, 1994, 43.
95. MURPHY, W.K., WINN, R.J., FOSSELLA, F.V., SHIN, D.M., HYNES, H.E., GROSS, H.M., DAVILLA, E., LEIMERT, J.: A phase II study of Taxol (NSC 125973) in patients with non-small cell lung cancer. Abstr. Proc. Am. Soc. Clin. Oncol., 11, 1992, 294.
96. MURPHY, W.K., WINN, R.J., HUBE, M., FOSSELLA, F.V., GOLDBERG, D., PRESANT, C.A., FLYNN, P.J., COLDMAN, B., CLEMENTS, S., RABER, M., HONG, W.K.: Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy. Abstr. 1224. Proc. Am. Soc. Clin. Oncol., 13, 1994, 363.
97. NABHOLTZ, J.M., GELMON, K., BONTENBAL, M., SPIELMANN, M., CLAVEL, M., SEEBER, S., CONTE, P., NAMER, M., BONNETERRE, J., FUMOLEAU, P., SULKES, A., SAUTER, CH., ROCHE, H., CALVERT, H.: Randomized trial of two doses of Taxol in metastatic breast cancer. An Interim analysis. Abstr. 42. Proc. Am. Soc. Clin. Oncol., 12, 1993, 60.
98. OZOLS, R.F., KILPATRIC, D., O'DWYER, P., JOHNSON, S., BOOKMAN, M.A., WALCZAK, J., ROWINSKY, E., MCGUIRE, W.P.: Phase I and pharmacokinetic study of Taxol and carboplatin in previously untreated patients with advanced epithelial ovarian cancer: A pilot study of Gynecologic Oncology Group. Abstr. 842. Proc. Am. Soc. Clin. Oncol., 12, 1993, 259.
99. PARAISO, D., RIXE, O., BOREL, C., AUCLERE, G., PETIT, T., NIZRI, D., COEFFIC, D.: A pilot study of Taxol, cisplatin and cyclophosphamide (PTC) in stage III-IV ovarian cancer: Preliminary results. Abstr. 803. Proc. Am. Soc. Clin. Oncol., 14, 1995, 283.
100. PAUL, D., DE VORE, R.D., HANDE, K.R., STEWART, S., MURPHY, B., BLANKE, C., GARRETT, A., LEWIS, M., JOHNSON, D.H.: Phase II trial of carboplatin (C) + paclitaxel (T) in advanced non-small cell lung cancer. Abstr. 1103. Proc. Am. Soc. Clin. Oncol., 14, 1995, 361.
101. PAUL, D.M., GARRETT, A.M., MESHAD, M., DEVORE, R.D., PORTER, L.L., JOHNSON, D.H.: A phase II trial of paclitaxel, 5-fluororuracil and leucovorin (TFL) in metastatic breast cancer (MBC). Abstr. 259. Proc. Am. Soc. Clin. Oncol., 14, 1995, 140.
102. PAWEL, J., WAGNER, H., GATZERMEIER, U., HECKMAYER, M., NEUHAUSS, R., SCHLÜTER, I., DIERGATEN, KL: Phase II study with Paclitaxel (Taxol) in advanced inoperable NSCLC. Abstr. 779. Ann. Oncol., Suppl. 8, 5, 1994, 155.
103. POBER, M., BAUEMHOFER, TH., SAMONIGG, H., FRITZ, E., LUDWIG, H.: Paclitaxel (Taxol) in extensively pretreated patients with advanced breast cancer. Abstr. 175. Ann. Oncol., Suppl. 8, 5, 1994, 35.
104. PRADOS, M., SCHOLD, C., SPENCE, A., BERGER, M., ALLISTER, L.M., MEHTA, M., GILBERT, M., FULTON, D., CHANG, S.: Phase II study Taxol in patients with recurrent malignant glioma: North American Brain Tumor Consortium. Abstr. 281. Proc. Am. Soc. Clin. Oncol., 14, 1995, 146.
105. + peripheral blood progenitor cells (PBSC) in patients with responding metastatic breast cancer (MBC) undergoing high dose chemotherapy. Abstr. 919. Proc. Am. Soc. Clin. Oncol., 14, 1995, 313.
106. REED, E., SAROSY, G., KOHN, E.: Phase I study of paclitaxel and cyclophosphamid in recurrent adenocarcinoma of the ovary. Abstr. . Proc. Am. Assoc. Cancer. Res., 35, 1994, 234.
107. RIGAS, J.D., FENNELLY, D., CHOU, D., MILLER, V., KRIS, M., SIROTNAK, F.: Phase I trial of sequential edatrexate followed by paclitaxel: A designed based on in vitro study. Abstr. 490. Ann. Oncol., Suppl. 5, 5, 1994, 198.
108. ROSENTHAL, C.J., IBRAHIM, A., RAMBHIA, H., BELLINA, D., DIPILLO, F.: Paclitaxel (Taxol) - mitoxantrone salvage therapy in metastatic carcinoma of the breast-phase I/II study. Abstr. 172. Proc. Am. Soc. Clin. Oncol., 13, 1994, 90.
109. ROTH, B.J., DREICER, R., EINHORN, L.H., NEUBERG, D., JOHNSON, D.H., SMITH, J.L., HUDES, G.R., SCHULTZ, S.M., LOEHRER, P.J.: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 12, 1994, 2264-2270.
110. ROTH, B., YEAP, B., WILDING, B., KASIMIS, B., MCLEOD, D.: Taxol in advanced hormone-refractory carcinoma of prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer, 72, 1993, 2457-2460.
111. ROWINSKY, E.K., BURKE, P.J., KARP, I.E., TUCKER, R.W., ETTINGER, D.S., DONEHOWER, R.C.: Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer. Res., 49, 1989, 4640-4647.
112. ROWINSKY, E.K., CAZENAVE, L.A., DONEHOWER, R.C.: Taxol: A novel investigational antimicrotubule agent J. Natl. Cancer. Inst., 82, 1990, 1247-1259.
113. ROWINSKY, E.K., GILBERT, M.R., MCGUIRE, W.P., NOE, D. A., GROCHOW, L.B., FORASTIERE, A.A., ETTINGER, D.S., LUBEJKO, B.G., CLARK, B., SARTORIUS, S.E.: Sequences of Taxol and cisplatin: A phase I pharmacologic study. J. Clin. Oncol., 9, 1991, 1692-1703.
114. ROWINSKY, E.K., ONETTO, N., CANETTA, R.M., ARBUCK, S. G.: Taxol: The first of the taxanes, an important new class of antitumor agents. Semin. Oncol., 19, 1992, 646-662.
115. ROWINSKI, E.K., SARTORIOUS, S.E., BOWLING, M.K., WAGNER, J.W., ETTINGER, D.S.: Paclitaxel on a 3-hour schedule and carboplatin in non small cell lung cancer: Use of maximally tolerated and clinically relevant single agens doses combination is feasible. Abstr. 1075. Proc. Am. Soc. Clin. Oncol., 14, 1995, 354.
116. ROWINSKY, E.K., WRIGHT, M., MONSARRAT, B., DONEHOWER, R.C.: Clinical pharmacology and metabolism of Taxol (paclitaxel): Update 1993. Ann. Oncol., Suppl. 6, 5, 1994, 7-16.
117. RUCHDESCHEL, I., WAGNER, H. JR., WILLIAMS, C., HEISE, M., HILSTRO, J.: Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer: The role of Taxol. Abstr. 1200. Proc. Am. Soc. Clin. Oncol., 13, 1994, 357.
118. SAROSY, G., KOHN, E., STONE, D.A., ROTHENBERG, M., JACOB, L., ADAMO, D.O., OGNIBENE, F.P., CUNNION, R. E., REED, E.: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J. Clin. Oncol., 10, 1992, 1165-1170.
119. SCHIFF, P.B., FANT, J., HORWITZ, S.B.: Promotion of microtubule assembly in vitro by Taxol. Nature, 22, 1979, 665-667.
120. SCHILLER, J.H., STORER, B., TUTSCH, K.: Phase I trial of 3-hours infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer (see comments). J. Clin. Oncol., 12, 1994, 241-248.
121. SEEWALDT, V.L., GREER, B.E., CAIN: Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am. J. Obstet. Gynecol., 6, 1994, 1666-1670.
122. SEIBEL, N., AMES, M., IVY, P., KRAILO, M., REID, J., KENT, P., REAMAM, G.: Phase I and pharmacologic study of paclitaxel in refractory pediatric leukemia: A childrens cancer group study. Abstr. 1068. Proc. Am. Soc. Clin. Oncol., 13, 1994, 324.
123. SEIDMAN, A.D., BARRETT, S., HUDIS, C., LEPORE, J., YAO, T.J., GILEWSKI, T., CURRIE, V., CROWN, J., HAKES, T., BASELGA, J., SKLARIN, N.: Three hour Taxol infusion as initial (I) and as salvage (S) chemotherapy of metastatic breast cancer (MBC). Abstr. 65. Proc. Am. Soc. Clin. Oncol., 13, 1994, 66.
124. SEIDMAN, A., CROWN, J., REICHMAN, B., HUDIS, C., YAO, T.J., FORSYT, P., CURRIE, V., HAKES, T., GILEWSKI, T., LEPORE, J., MARKS, L., FAIN, K., ARBUCK, S., NORTON, L.: Lack of clinical crossresistance of Taxol with anthracycline in the treatment of metastatic breast cancer. Abstr. 53. Proc. Am. Soc. Clin. Oncol., 12, 1993, 63.
125. SEIDMAN, A.D., LEPORE, J., YAO, T.J., KORTMANSKY, J., REN, L.: Prognostic value of baseline quality of life (QOL) assessment metastatic breast cancer (MBC). Abstr. 1493. Proc. Am. Soc. Clin. Oncol., 13, 1994, 430.
126. SEIDMAN, A.D., NORTON, L., REICHMANN, B.S., CROWN, J. P.A., YAO, T.J., HEELAN, R., HAKES, T.B., LEBWOHL, D.E., GILEWSKI, T.A.: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin. Oncol., Suppl. 3, 4, 1993, 40-45.
127. SHEA, T., GRAHAM, M., STEAGALL, A., BERNARD, S., WILEY, J., MOORE, D., GONZALES, P., JOHNSTON, C., BRECHER, M., BENTLEY, S.: Multiple cycles of high dose Taxol plus carboplatin with G-CSF (Filgrastim) and peripheral blood progenitor cell support. Abstr. 395. Proc. Am. Soc. Clin. Oncol., 13, 1994, 153.
128. SLEDGE, G.W., ROBERT, N., SPARANO, J.A., COBELIGH, M., GOLDSTEIN, L.J., NEUBERG, D., ROWINSKY, E., BAUGHMAN, C.: Paclitaxel (Taxol) doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin. Oncol., Suppl. 8, 5, 1994, 15-18.
129. SLEDGE, G., SPARANO, J., MCCASKILL-STEVENS, W., COBLEIGH, M., ROBERT, N., BAUGHMAN, C., NEUBERG, D., ROWINSKY, E.: Pilot trial of alternating Taxol and adriamycin for metastatic breast cancer. Abstr. 85. Proc. Am. Soc. Clin. Oncol., 12, 1993, 71.
130. STEMMER, S., JONES, R., BEATMAN, S., PURDY, M., MYERS, S., SHPALL, E.: Intensive Taxol/cyclophosphamide/cisplatin with autologous hematopoetic cell support Abstr. 222. Proc. Am. Soc. Clin. Oncol., 13, 1994, 105.
131. STEWART, D.J., TOMIAK, E., GOSS, G., LOGAN, D., EVANS, W.K., SOLTYS, K., GALLANT, G., DULUDE, H.: Paclitaxel plus low dose hydroxyurea as second line therapy in non-small cell lung cancer. Abstr. 1126. Proc. Am. Soc. Clin. Oncol., 14, 1995, 367.
132. STIERLE, A., STROBEL, G., STIERLE, D.: Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific New. Science, 260, 1993, 214-216.
133. SWAIN, S., HONING, S., WALTON, L.: Phase II trial of paclitaxel (Taxol) as first line chemotherapy for metastatic breast cancer (MBC). Abstr. 227. Proc. Am. Soc. Clin. Oncol., 14, 1995, 132.
134. TEN BOKKEL HUININK, W.W., VEENHOF, C.H.N. HUIZIG, M., RODENHUIS, S., DUBBELMAN, R., DALESIO, O., BEIJNEN, J.H., DEPAUW, L., WINOGRAD, B.: Carboplatin and Paclitaxel (Taxol) in patients with advanced ovarian cancer, a dose finding study. Abstr. 495. Ann. Oncol., Suppl. 8, 5, 1994, 99.
135. TESTER, W., COHN, J., DESAI, A., REARDON, D., COHEN, M.: Phase II study of short infusion paclitaxel in patients with stage IV non-small cell lung cancer. Abstr. 1189. Proc. Am. Soc. Clin. Oncol., 14, 1995, 382.
136. THIGPEN, T., BLESSING, J., BALL, H., BARRETT, R.J.: Phase II trial of Taxol as second line therapy for ovarian carcinoma. Abstr. 604. Proc. Am. Soc. Clin. Oncol., 9, 1990, 156.
137. THIGPEN, T., BLESSENG, J., BALL, H., HUMMEL, S.J., BARRETT, R.J.: Phase n trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J. Clin. Oncol., 9, 1994, 1748-1753.
138. THORNTON, D., SINGH, K., PUTZ, B., GAMS, R., SCHULLER, D., SMITH, R.: A phase II trial of Taxol in squamous ceil carcinoma of the head and neck. Abstr. 933. Proc. Am. Soc. Clin. Oncol., 13, 1994, 288.
139. TISHLER, R.B., GEARD, C.R., HALL, E.J., SCHIFF, P.B., PHIL, D.: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res., 52, 1992, 3495-3497.
140. TOLCHER, A., COWAN, K.H., RILEY, J., GOLDSPIEL, B., DENICOFF, A., MCCABE, M., SOLOMON, D., GOSSARD, M., NOONE, M., O'SHAUGHNESSY, J.: Phase I study of paclitaxel (T) and cyclophosphamid (CTX) and G-CSF in metastatic breast cancer. Abstr. 93. Proc. Am. Soc. Clin. Oncol., 13, 1994, 73.
141. TRIMBLE, E.L., ADAMS, J.D., VENA, D.: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol., 11, 1993, 2405-2410.
142. UZIELY, B., DELAFLOR-WEISS, E., RUSSELL, C.: Refractory breast cancer treatment with Taxol: Correlations with baseline immunohistochemistry for p-glycoprotein (Pgp). Abstr. 435. Eur. J. Cancer, 29A, 1993.
143. UZIELY, B., GROSHEN, S., JEFFERS, S., MORRIS, M., RUSSELL, C., ROMAN, L., MUDERSPACH, L., MUGGIA, F.: Paclitaxel (Taxol) in heavily pretreated ovarian cancer: Antitumor activity and complications. Ann. Oncol., 5, 1994, 827-833.
144. VAFAI, D., ISRAEL, V., ZARETSKY, S., NATALE, R.B.: Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC). Abstr. 1067. Proc. Am. Soc. Clin. Oncol., 14, 1995, 352.
145. VERMORKEN, J., HUIZING, M.T., LIEFTTNG, A.J.M., POSTMA, A.J.M., DEPAUW, L., TEN BOKKEL HUININK, W. W.: High-dose Taxol with G-CSF in patients with advanced breast cancer refractory to anthracycline therapy. Abstr. 435. Eur. J. Cancer, Suppl. 6, 29A, 1993, 83.
146. VIALLET, J., BOUCHER, L., GALLANT, G.: In vitro interaction between paclitaxel (TAX) and other agents in human non-small cell lung cancer cell lines: Antagonism with etoposide(VP-16) and doxorubicin. Abstr. 1233. Proc. Am. Soc. Clin. Oncol., 13, 1994, 367.
147. VOGELZANG, N.J., HERNDON, J., CLAMON, G.H., MAUER, A. M., COOPER, M.R., GREEN, M.R.: Paclitaxel (Taxol) for malignant mesothelioma: A phase II study of the cancer and leukemia group B (CALGB 9234). Abstr. 1382. Proc. Am. Soc. Clin. Oncol., 13, 1994, 405.
148. VUKELJA, S.J., BAKER, W.J, BURRELL, L.M., LEE, L.M., JENKINS, T.R., RINALDI, D., MCCARTY, M.J., ATKINS, Y., KULA, A.: High-dose paclitaxel, cyclophosphamide, and cisplatin with stem cell support in treatment of metastatic breast cancer. Abstr. 185. Proc. Am. Soc. Clin. Oncol., 14, 1995, 121.
149. WALL, M.E., WANI, M.C.: A preliminary report dealing only with the isolation was reported at the 153rd National Meeting of the American Chemical Society, Miami Beach, 1967, M-006.
150. WANI, M.C., TAYLOR, H.L., WALL, M.E.: Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93, 2325-2327.
151. WASSERHEIT, C., ALTER, R., SPEYER, J., HOCHSTER, H., ORATZ, R., WERNZ, J., CRACHOUA, A., MEYERS, M., SORICH, J., DOWNEY, A., FRIEDBERG, A., BLUM, R.: Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer. Abstr. 204. Proc. Am. Soc. Clin. Oncol., 13, 1994, 100.
152. WIERNIK, P.H., EINZIG, A.I.: Taxol in malignant melanoma. Second National Cancer Inst. Workshop on Taxol and Taxus. Alexandria, September 23-24, 1992, 31-33.
153. WIERNIK, P.H., SCHWARTZ, E.L., STRAUMANN, J.J.: Phase I clinical and pharmacokinetic study of Taxol. Cancer. Res., 47, 1987, 2485-2493.
154. WILSON, W.H., BERG, S.L., BRYANT, G., WITTES, R.E., BATES, S., FOJO, A., STEINBERG, S.M., GOLDSPIEL, B. R., HERDT, J., O'SHAUGHNESSY, J.: Paclitaxel in doxorubicm-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hrs infusion. J. Clni. Oncol., 8, 1994, 1621-1629.
155. WILSON, W.H., CHABNER, B.A., BRYANT, G., BATES, S., FOJO, A., REGIS, J., JAFFE, E.S., STEINBERG, S.M., GOLDSPIEL, B.R., CHESON, D.B., WITTES, R.E.: Phase II study of paclitaxel in relapsed lymphomas. I Clin. Oncol., 2, 1995, 381-386.
156. YEH, A., OLAH, E., WENDEL, J.J., SLEDGE, G.W., JR., WEBER, G.: Synergistic action of Taxol with tiazofurin and methotrexate in human breast cancer cells: Schedule-dependence. Life Sci., 24, 1994, 431-435.
157. YOUNES, A., SARRIS, A., MCLAUGHLIN, P., ROMAGUERA, J., JENDIROBA, D., SWAN, F., RODRIGUEZ, A., HAGEMEISTER, F., MOORE, D., CABANILLAS, F.: Phase II trial of Taxol given as a 3-hours infusion every 3 weeks in relapsed Non-Hodgkin's lymphoma (NHL). Abstr. 1267. Am. Soc. Clin. Oncol., 13, 1994, 61.
158. ZIMMERMAN, T.M., MICK, R., GRINBALL, D.L., WILLIAMS, S.F.: High-dose cyclophosphamide (CY), thiotepa (TTP) with escalating continuous infusion Taxol (TXL) and autologous stem cell rescue (ASCR) for metastatic breast cancer. A phase I/II study. Abstr. 977. Proc. Am. Soc. Clin. Oncol., 14, 1995, 328.